Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Genprex Inc (NQ: GNPX ) 1.900 -0.030 (-1.55%) Streaming Delayed Price Updated: 12:29 PM EDT, Jul 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 13,365 Open 1.960 Bid (Size) 1.900 (1) Ask (Size) 1.930 (2) Prev. Close 1.930 Today's Range 1.900 - 2.000 52wk Range 0.1825 - 7.990 Shares Outstanding 59,409,822 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News 12 Health Care Stocks Moving In Friday's Intraday Session May 31, 2024 Via Benzinga GNPX Stock Earnings: Genprex Beats EPS for Q1 2024 May 20, 2024 GNPX stock results show that Genprex beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Performance YTD +712.01% +712.01% 1 Month -39.68% -39.68% 3 Month -36.02% -36.02% 6 Month +712.01% +712.01% 1 Year +97.93% +97.93% More News Read More Clinical Trials Commenced for Promising Acclaim-3 Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer: Genprex, Inc. (NASDAQ: GNPX) May 14, 2024 Via Get News New Company Officers Appointed After Promising Preclinical Data on Gene Therapy for Anti-Tumor Mechanisms with Ability to Trigger Cancer Cell Death: Genprex, Inc. (NASDAQ: GNPX) May 13, 2024 Via Get News BioMedNewsBreaks — Genprex Inc. (NASDAQ: GNPX) Announces Participation at Upcoming Investor, Industry Events May 01, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Product Safety 12 Health Care Stocks Moving In Friday's Pre-Market Session April 26, 2024 Via Benzinga BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Positive Preclinical Data Supporting NPRL2 Gene Therapy April 02, 2024 Via Investor Brand Network Exposures Product Safety BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Closes on $6.5M Registered Direct Offering March 25, 2024 Via Investor Brand Network Exposures Product Safety TechMediaBreaks – Genprex Inc. (NASDAQ: GNPX) Closes on $6.5M Registered Direct Offering March 25, 2024 Via Investor Brand Network Exposures Product Safety 12 Health Care Stocks Moving In Tuesday's Intraday Session March 19, 2024 Via Benzinga TinyGemsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $6.5M Registered Direct Offering March 19, 2024 Via Investor Brand Network Exposures Product Safety InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $6.5M Registered Direct Offering March 19, 2024 Via Investor Brand Network Exposures Product Safety InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Adds Korean Patent for Leading Drug Candidate to Growing International Patent Portfolio March 13, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Product Safety Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session March 06, 2024 Via Benzinga InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Preclinical Data to be Presented at Upcoming AACR Annual Meeting March 06, 2024 Via Investor Brand Network Exposures Product Safety BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces New Research Collaborations, Expansion of Nonclinical Programs into New Therapeutic Indications February 07, 2024 Via Investor Brand Network Exposures Product Safety InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces New Research Collaborations, Expansion of Nonclinical Programs into New Therapeutic Indications February 07, 2024 Via Investor Brand Network Exposures Product Safety BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation at This Month’s BIO CEO & Investor Conference February 06, 2024 Via Investor Brand Network Exposures Product Safety BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Phase2a Expansion of Acclaim-1 Clinical Study Enrolls, Doses First Patient February 05, 2024 Via Investor Brand Network Exposures Product Safety InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Phase2a Expansion of Acclaim-1 Clinical Study Enrolls, Doses First Patient February 05, 2024 Via Investor Brand Network Exposures Product Safety Dow Turns Lower; Federal Reserve Keeps Rates Unchanged January 31, 2024 Via Benzinga Topics Economy Stocks Exposures Interest Rates US Equities Why AMD Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session January 31, 2024 Via Benzinga Crude Oil Down 2%; Alphabet Shares Fall After Q4 Results January 31, 2024 Via Benzinga Topics Stocks Exposures Fossil Fuels US Equities 12 Health Care Stocks Moving In Thursday's Pre-Market Session January 11, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Intraday Session January 09, 2024 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
